Royalty Pharma plc (NASDAQ: RPRX): Do Not Miss The Gain Train

Royalty Pharma plc (RPRX) concluded trading on Wednesday at a closing price of $28.80, with 3.62 million shares of worth about $104.39 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 7.42% during that period and on April 3, 2024 the price saw a loss of about -2.17%. Currently the company’s common shares owned by public are about 446.69M shares, out of which, 378.54M shares are available for trading.

However, the stock later moved at a day high price of 30.64, or with a loss of -2.17%. Stock saw a price change of -4.73% in past 5 days and over the past one month there was a price change of -3.65%. Year-to-date (YTD), RPRX shares are showing a performance of 2.53% which decreased to -20.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $25.92 but also hit the highest price of $36.74 during that period. The average intraday trading volume for Royalty Pharma plc shares is 2.63 million. The stock is currently trading -4.29% below its 20-day simple moving average (SMA20), while that difference is down -3.38% for SMA50 and it goes to -0.68% lower than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Royalty Pharma plc (NASDAQ: RPRX) currently have 446.69M outstanding shares and institutions hold larger chunk of about 68.99% of that.

The stock has a current market capitalization of $12.86B and its 3Y-monthly beta is at 0.45. PE ratio of stock for trailing 12 months is 11.36, while it has posted earnings per share of $2.54 in the same period. Its PEG reads 3.55 and has Quick Ratio of 7.90 while making debt-to-equity ratio of 0.94. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 2.00% while standing at 1.81% over the month.

Stock’s fiscal year EPS is expected to drop by -12.79% while it is estimated to increase by 7.17% in next year. EPS is likely to grow at an annualized rate of 3.20% for next 5-years, compared to annual growth of 2.23% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on June 14, 2022 offering a Buy rating for the stock and assigned a target price of $47 to it. Coverage by Scotiabank stated Royalty Pharma plc (RPRX) stock as a Sector outperform in their note to investors on May 13, 2022, suggesting a price target of $53 for the stock. On April 27, 2022, Goldman Initiated their recommendations, while on April 14, 2022, JP Morgan Upgrade their ratings for the stock with a price target of $50. Stock get an Overweight rating from Morgan Stanley on April 06, 2022.

Most Popular

Related Posts